EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Infections after chimeric antigen receptor (CAR)‐T‐cell therapy for hematologic malignancies

Eleftheria Kampouri iD, Jessica S Little, Kai Rejeski, Oriol Manuel iD, Sarah P Hammond, Joshua A Hill

Transplant Infectious Disease · 2023-11 · 25 (S1)

DOI: 10.1111/tid.14157 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Transplant Infectious Disease, online erschienen am 03.10.2023. Verfasst von Eleftheria Kampouri und 5 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Hematologic Neoplasms, Cytomegalovirus Infections. Die Arbeit wurde bisher 103-mal zitiert (Crossref) und nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chimeric antigen receptor (CAR)‐T‐cell therapies have revolutionized the management of acute lymphoblastic leukemia, non‐Hodgkin lymphoma, and multiple myeloma but come at the price of unique toxicities, including cytokine release syndrome, immune effector cell‐associated neurotoxicity syndrome, and long‐term “on‐target off‐tumor” effects.

Methods

All of these factors increase infection risk in an already highly immunocompromised patient population. Indeed, infectious complications represent the key determinant of non‐relapse mortality after CAR‐T cells. The temporal distribution of these risk factors shapes different infection patterns early versus late post‐CAR‐T‐cell infusion. Furthermore, due to the expression of their targets on B lineage cells at different stages of differentiation, CD19, and B‐cell maturation antigen (BCMA) CAR‐T cells induce distinct immune deficits that could require different prevention strategies. Infection incidence is the highest during the first month post‐infusion and subsequently decreases thereafter. However, infections remain relatively common even a year after infusion.

Results

Bacterial infections predominate early after CD19, while a more equal distribution between bacterial and viral causes is seen after BCMA CAR‐T‐cell therapy, and fungal infections are universally rare. Cytomegalovirus (CMV) and other herpesviruses are increasingly breported, but whether routine monitoring is warranted for all, or a subgroup of patients, remains to be determined. Clinical practices vary substantially between centers, and many areas of uncertainty remain, including CMV monitoring, antibacterial and antifungal prophylaxis and duration, use of immunoglobulin replacement therapy, and timing of vaccination.

Conclusion

Risk stratification tools are available and may help distinguish between infectious and non‐infectious causes of fever post‐infusion and predict severe infections. These tools need prospective validation, and their integration in clinical practice needs to be systematically studied. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenHematologic NeoplasmsCytomegalovirus InfectionsHumansB-Cell Maturation AntigenCell- and Tissue-Based TherapyNeurotoxicity Syndromes

Stichwörter der Autor:innen

BCMACAR-T-cell therapyCD19infectionspredictionpreventionrisk stratification

Substanzen

Receptors, Chimeric Antigencell-associated neurotoxicityB-Cell Maturation Antigen

Autor:innen und Institutionen

  • Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Medicine III-Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany.
  • German Cancer Consortium (DKTK), Munich site, and German Cancer Research Center, Heidelberg, Germany.

ORCID-Profile: Eleftheria Kampouri, Oriol Manuel

Zitieren

APA

Kampouri, E., Little, J. S., Rejeski, K., Manuel, O., Hammond, S. P., & Hill, J. A. (2023). Infections after chimeric antigen receptor (CAR)‐T‐cell therapy for hematologic malignancies. Transplant Infectious Disease, 25(S1). https://doi.org/10.1111/tid.14157

Vancouver

Kampouri E, Little JS, Rejeski K, Manuel O, Hammond SP, Hill JA. Infections after chimeric antigen receptor (CAR)‐T‐cell therapy for hematologic malignancies. Transplant Infectious Disease. 2023;25(S1). doi:10.1111/tid.14157

BibTeX
@article{Kampouri2023,
  author = {Kampouri, Eleftheria and Little, Jessica S and Rejeski, Kai and Manuel, Oriol and Hammond, Sarah P and Hill, Joshua A},
  title = {Infections after chimeric antigen receptor (CAR)‐T‐cell therapy for hematologic malignancies},
  journal = {Transplant Infectious Disease},
  year = {2023},
  volume = {25},
  number = {S1},
  doi = {10.1111/tid.14157}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche